https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4
Skip to content 
Merck & Co. Inc. (NYSE: MRK) on Tuesday reported lower sales and adjusted earnings for the second quarter of 2025. The company also announced the acquisition of Verona Pharma plc. Second-quarter sales were $15.8 billion, compared to $16.1 billion in the prior year quarter. Pharmaceutical sales declined by 2% while Animal Health sales grew by 11%. The company reported … Read more
Merck & Co. signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Tuesday, April 8, 2025. Michael Nagle | Bloomberg | Getty Images Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches … Read more
© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal InformationFORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive … Read more
The Food and Drug Administration on Monday approved Merck’s shot designed to protect infants from respiratory syncytial virus during their first season of the virus, bringing to market a rival to a similar treatment from Sanofi and AstraZeneca. The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead … Read more
Merck is following Johnson & Johnson’s lead and reporting an expected financial hit from tariffs imposed by the Trump administration. In an April 24 earnings call, executives said they expect $200 million in tariff-related costs in 2025. Merck lowered its full-year profit expectations from $8.88–$9.03 per share to $8.82–$8.97 per share. The news comes a week after J&J executives … Read more
Merck & Co. Inc. (NYSE: MRK) Thursday reported an increase in adjusted earnings for the first quarter of 2025, while the pharma company’s sales remained broadly unchanged. First-quarter sales were $15.5 billion, compared to $15.8 billion in the prior year quarter. Pharmaceutical sales declined by 3% while Animal Health sales grew by 5%. The company reported … Read more
Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare industry. Just last month, AWS and General Catalyst announced their partnership to speed up the development and deployment of healthcare AI tools. GE Healthcare teamed up with AWS to build generative AI for medical use in 2024. Now, a … Read more
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings. Read More
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the fourth quarter of 2024, aided by a 7% increase in sales. Fourth-quarter worldwide sales increased 7% year-over-year to $15.6 billion, with Pharmaceutical and Animal Health revenues growing 7% and 9% respectively. The company reported a net profit of … Read more
https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4